Integration of Network Biology and Imaging to Study Cancer Phenotypes and ResponsesYe Tian, Guoqiang Yu, Olga Rodriguez et al.|IEEE Transactions on Computational Biology and Bioinformatics|2014Cited by 15
HER family protein expression and activation predicts response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL.Julia Wulfkuhle, Denise M. Wolf, Christina Yau et al.|Journal of Clinical Oncology|2019Cited by 4
Association of activation levels of TIE2 with response to the angiogenesis inhibitor trebananib in HER2+ patients in the I-SPY 2 trial.Rosa I. Gallagher, Emanuel Petricoin, Julia Wulfkuhle et al.|Journal of Clinical Oncology|2018Cited by 2
Protein signal pathway mapping: Screening potential drug targets for Multiple MyelomaAmy VanMeter, Lance A. Liotta, Rosa I. Gallagher et al.|Cancer Research|2008Cited by 0
Abstract P1-05-20: Validation of the HER2 Activation Response Predictive Signature (HARPS) as a Predictive Biomarker for HER2+ Therapy Response in the Neoadjuvant SettingEmanuel Petricoin, Shridar Ganesan, Julia Wulfkuhle et al.|Clinical Cancer Research|2025Cited by 0